PT-141 for Women: Evidence for Low Desire, Dosing, Side Effects

Key takeaways

• PT-141 (bremelanotide) is approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), the only peptide with an FDA approval for low desire; the label says it is not indicated for postmenopausal women or men.
• In the two 24-week RECONNECT trials (1,247 premenopausal women, mean age 39), desire scores rose 0.35 points more than placebo on a 1.2-to-6 scale and distress fell 0.33 points more; satisfying sexual events did not change.
• The labeled dose is 1.75 mg under the skin at least 45 minutes before sex, at most one dose in 24 hours and eight a month, stopped after eight weeks if nothing improves.
• Nausea affects 40% of women (1% on placebo), 18% stop for side effects, every dose raises blood pressure for a few hours, and 1% develop patches of darkened skin. It is contraindicated in uncontrolled hypertension and known cardiovascular disease.
• After menopause there is no bremelanotide evidence; transdermal testosterone and, under 65, flibanserin have the trials. Compounded PT-141 costs $60 to $200 a month and is legal from a licensed pharmacy within limits; nasal sprays have never been tested at the doses sold.

PT-141 for women has a clearer answer than most peptide questions, because the drug went through FDA review. Bremelanotide is approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder: low desire that causes distress and is not explained by a medical or psychiatric condition, a relationship problem or a medication. In two 24-week trials it raised desire a little, lowered distress a little, did not increase satisfying sexual events, and caused nausea in four women out of ten. It has no evidence in postmenopausal women, and the label says it is not indicated for them. The PT-141 profile covers the compound in full, including the male data, sermorelin for women covers the other peptide marketed to women, and peptides for menopause ranks what has evidence after menopause.

What the trials found

The approval rests on RECONNECT, two identical phase 3 trials that randomized 1,267 premenopausal women with HSDD to bremelanotide 1.75 mg or placebo, self-injected as needed for 24 weeks; 1,247 were in the safety population, the mean age was 39, and 97% were enrolled at US sites (Kingsberg 2019). The co-primary endpoints were the desire domain of the Female Sexual Function Index (FSFI), which runs from 1.2 to 6, and a single distress question scored 0 to 4.

Two other findings frame those numbers. In the 12-week dose-finding trial of 327 premenopausal women, the pooled 1.25 and 1.75 mg doses added 0.7 satisfying sexual events a month against 0.2 on placebo (Clayton 2016). After RECONNECT, 684 women entered a 52-week open-label extension with no placebo group and 272 completed it; scores kept improving in those who stayed, and nausea (40.4%) remained the most common drug-related event (Simon 2019).

The effect is statistically solid and small, satisfying sexual encounters did not become more frequent, and tolerability decides who benefits at all. An independent re-analysis of the FDA application reproduced the efficacy numbers and, given the dropouts and the preference for placebo, concluded that the drug "is generally not useful" (Spielmans 2021); the label describes a meaningful benefit for responders. Both describe the same data.

No evidence after menopause

Postmenopausal women were excluded from RECONNECT and from the dose-finding trial, and the label's limitations of use state that Vyleesi "is not indicated for the treatment of HSDD in postmenopausal women or in men," adding that safety and effectiveness have not been established in geriatric patients (Vyleesi label). We found no published study of bremelanotide at the labeled dose in postmenopausal women as of October 2026; a clinic prescribing PT-141 to a 58-year-old is relying on data from women with a mean age of 39.

What has evidence after menopause is not a peptide. The 2019 global consensus statement on testosterone therapy for women, endorsed by eleven societies, concludes that testosterone at doses approximating premenopausal physiological concentrations improves sexual function in postmenopausal women with HSDD, with mild acne and hair growth as side effects; it does not recommend oral testosterone, injectables, pellets or compounded preparations (Davis 2019). The meta-analysis behind it, 36 randomized trials with 8,480 participants, put the gain at 0.85 satisfying sexual events a month over placebo or comparator (Islam 2019). No female product is approved in the United States, so this is off-label use of a fraction of a male gel, with a baseline testosterone level and a repeat at three to six weeks.

Label dosing and limits

Doses closer together than 24 hours add to the blood pressure effect, and daily dosing produced skin darkening in 38% of women within eight days in a separate study (Vyleesi label).

Compounded versions. Compounded bremelanotide usually arrives as a 10 mg vial; reconstituted with 2 mL of bacteriostatic water it gives 5 mg/mL, so the labeled 1.75 mg dose is 0.35 mL, 35 units on a U-100 insulin syringe; 1 mg is 20 units and 2 mg is 40 units. Telehealth prescriptions for women are often 1 to 2 mg, and 1 mg is 40% below the only dose shown to work. Nasal sprays labeled around 1 to 2 mg a spray have no efficacy data: the nasal studies that worked used 7.5 to 20 mg, and that program was shelved over blood pressure. Run your own numbers in the reconstitution calculator and the units guide, and trust the pharmacy label over either.

Side effects, from the label

The figures come from 627 women on bremelanotide and 620 on placebo in the phase 3 trials (Vyleesi label).

Nausea starts within about an hour and lasts about two; 21% had it after the first dose and about 3% after later ones, 13% took an anti-nausea drug, 8% quit because of it, and ondansetron beforehand did not prevent it.

Blood pressure and heart rate. Each dose raises systolic pressure by up to 6 mmHg and diastolic by 3 mmHg, peaking two to four hours after injection, with a fall in heart rate of up to 5 beats a minute; both return to baseline within about 12 hours. The label contraindicates Vyleesi in uncontrolled hypertension and known cardiovascular disease, does not recommend it at high cardiovascular risk, and asks for blood pressure checks during treatment.

Focal hyperpigmentation. Darkened patches on the face, gums or breasts in 1% of women at up to eight doses a month and none on placebo; with daily dosing, 38% within eight days, more often in darker skin, and not always resolved after stopping.

Interactions. Bremelanotide may slow gastric emptying and reduce the absorption of oral drugs; the label says to avoid it with oral naltrexone for alcohol or opioid dependence and with oral drugs that depend on threshold concentrations, such as antibiotics.

Who should not use it, or only with caution: uncontrolled hypertension or known cardiovascular disease (contraindicated) and high cardiovascular risk (not recommended); severe kidney or liver impairment (caution); any possibility of pregnancy without effective contraception, since the label requires contraception and discontinuation if pregnancy is suspected; breastfeeding, for which there are no data; oral naltrexone.

Compounded PT-141, the law and the cost

Bremelanotide is the active ingredient of an approved drug, which is why a state-licensed 503A pharmacy may compound it on a prescription; it has never been on FDA's Category 2 list. The limit is the federal rule against routinely compounding what is essentially a copy of a commercially available drug: a compounded 1.75 mg injection that mirrors Vyleesi needs a prescriber-documented clinical reason, which is partly why compounded PT-141 comes in other strengths or as a nasal spray; the legal tracker has the detail. Vials sold online as research PT-141 are unapproved drugs, and FDA named PT-141 in its August 24, 2026 warning letters to five online vendors. As of October 2026, compounded bremelanotide runs about $60 to $200 a month, cash, and brand Vyleesi lists at several hundred dollars for a carton of four autoinjectors; the cost guide has the full table.

Alternatives

• Flibanserin (Addyi). A daily non-peptide pill, 100 mg at bedtime, indicated since December 2025 for women under 65 with acquired, generalized HSDD regardless of menopausal status, with the same eight-week stop rule and a boxed warning about low blood pressure and fainting with alcohol (Addyi label). For a premenopausal woman the comparison is a nightly pill with alcohol rules against an injection with nausea, and small effects either way.
• Transdermal testosterone after menopause, as above: the option with randomized evidence, off-label, with monitoring (Davis 2019).
• Treating the cause. The HSDD definition excludes low desire explained by a medication (antidepressants are the usual culprit), a medical or psychiatric condition, or the relationship; for painful or dry sex after menopause, low-dose vaginal estrogen is the treatment, and bremelanotide is not.

Bottom line

PT-141 for women is a real drug with a small effect. A premenopausal woman with a proper HSDD diagnosis, normal blood pressure and reliable contraception can expect a modest rise in desire, a modest fall in distress, a 40% chance of nausea and no change in how often sex is satisfying, with a decision at eight weeks about whether to continue. A postmenopausal woman has no bremelanotide data and does have testosterone data. A compounded vial is the same molecule at a dose that may not match the label; a nasal spray is an untested dose of a formulation the manufacturer abandoned.

Frequently asked questions

+−What is the PT-141 dosage for women?

The only labeled dose is 1.75 mg under the skin of the abdomen or thigh, as needed, at least 45 minutes before anticipated sex, with no more than one dose in 24 hours and no more than eight doses a month; the label says to stop after eight weeks if there is no improvement. In a 10 mg vial reconstituted with 2 mL, 1.75 mg is 0.35 mL, or 35 units on a U-100 insulin syringe. Compounded prescriptions of 1 mg are below the only dose shown to work. These are label doses, not recommendations; the pharmacy label decides.

+−Does PT-141 work for women?

For premenopausal women with acquired, generalized HSDD, a little. In two 24-week trials of 1,247 women, desire scores rose 0.35 points more than placebo on a 1.2-to-6 scale and distress fell 0.33 points more; both were statistically significant, and the number of satisfying sexual events did not change. Nausea affected 40% and 18% stopped for side effects. Whether that is worth it is an individual decision, and the label builds in an eight-week checkpoint.

+−Is PT-141 approved for postmenopausal women?

No. Vyleesi is approved for premenopausal women only; the label states it is not indicated for HSDD in postmenopausal women or in men and that safety and effectiveness have not been established in geriatric patients. Postmenopausal women were excluded from the trials, and no published study has tested the labeled dose after menopause. The treatment with randomized evidence after menopause is transdermal testosterone at premenopausal physiological doses, which adds about one satisfying sexual event a month over placebo.

+−How long does PT-141 take to work in women?

Blood levels peak about an hour after injection, which is why the label says to inject at least 45 minutes before anticipated sexual activity; the label states that the duration of the effect on desire is unknown and that women may adjust the timing from their own experience of the effect and of nausea, which typically starts within an hour and lasts about two hours. Over weeks, the trials measured desire at 24 weeks, and the label says to stop at 8 weeks if nothing has improved.

+−What are the side effects of PT-141 in women?

In the approval trials: nausea 40% (versus 1.3% on placebo), flushing 20%, injection-site reactions 13%, headache 11%, vomiting 5%; 18% stopped for side effects versus 2% on placebo. Each dose raises systolic blood pressure by up to 6 mmHg for a few hours and slows the heart by up to 5 beats a minute. Patches of darkened skin on the face, gums or breasts occurred in 1% of women at up to eight doses a month and in 38% with daily dosing, and did not always fade. It is contraindicated in uncontrolled hypertension and known cardiovascular disease.

+−Is PT-141 the same as Vyleesi?

Same molecule, different products. Vyleesi is the FDA-approved 1.75 mg autoinjector with a label, a tested potency and a manufacturer. Compounded PT-141 is bremelanotide prepared by a state-licensed pharmacy on a prescription, usually as a 10 mg vial or a nasal spray, legal because bremelanotide is a component of an approved drug but subject to the rule against copying a commercially available product. Research-labeled PT-141 vials sold online are unapproved drugs with no verified content, and FDA named PT-141 in its August 2026 warning letters to five vendors.

+−What is the most effective peptide for increasing female arousal?

Bremelanotide is the only peptide approved for a sexual indication in women, so by default it is the most proven, but it is approved for desire, not arousal, and the effect is small: about 0.3 points on a 1.2-to-6 desire scale and no change in satisfying sexual events. Kisspeptin has shown effects on brain responses to sexual stimuli in small infusion studies and is not a prescribable product. For arousal and lubrication problems after menopause, low-dose vaginal estrogen has far more evidence than any peptide.

+−Can women use PT-141 nasal spray instead of the injection?

The nasal route is where bremelanotide started, and the nasal doses studied in the 2000s were 7.5 to 20 mg; the manufacturer dropped the spray after FDA named blood pressure as its greatest safety concern, and the drug was approved only as a 1.75 mg injection. Compounded sprays labeled around 1 to 2 mg a spray deliver a fraction of the studied nasal doses, their absorption has not been measured, and no trial has tested them. The PT-141 profile covers the nasal studies.

Sources

1. LabelCosette Pharmaceuticals. VYLEESI (bremelanotide injection) prescribing information, revised March 2024. DailyMed. (2024)
2. StudyKingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019;134:899-908. (2019)
3. ReviewSpielmans GI. Re-analyzing phase III bremelanotide trials for 'hypoactive sexual desire disorder' in women. J Sex Res 2021;58:1085-105. (2021)
4. StudySimon JA et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019;134:909-17. (2019)
5. StudyClayton AH et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) 2016;12:325-37. (2016)
6. LabelSprout Pharmaceuticals. ADDYI (flibanserin) tablets prescribing information; indication revised December 2025 to women under 65 with acquired, generalized HSDD. DailyMed. (2025)
7. GuidelineDavis SR et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab 2019;104:4660-6. (2019)
8. ReviewIslam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol 2019;7:754-66. (2019)